Comparative Pharmacology
Head-to-head clinical analysis: OZOBAX versus PARSIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OZOBAX versus PARSIDOL.
OZOBAX vs PARSIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OZOBAX (carisoprodol) is a centrally acting skeletal muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is thought to be related to its sedative properties and its metabolite, meprobamate, which has anxiolytic and sedative effects. Carisoprodol acts as a GABA-A receptor agonist and may also inhibit interneuronal activity in the spinal cord and reticular formation.
Parsidol (ethopropazine) is a phenothiazine derivative that acts as an anticholinergic agent. It inhibits the action of acetylcholine at muscarinic receptors, thereby reducing cholinergic activity in the basal ganglia and restoring the balance between dopaminergic and cholinergic neurotransmission. It also has some dopamine reuptake inhibition and antihistaminic properties.
OZOBAX (baclofen) oral: Initial 5 mg three times daily, may increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg four times daily). Intrathecal: Test dose 50-100 mcg, then continuous infusion via pump 22-900 mcg/day.
Oral: 2.5-5 mg twice daily, gradually increased to 5-10 mg three times daily; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function. This supports twice-daily dosing in most patients.
Terminal elimination half-life: 12-24 hours (prolonged in elderly and renal impairment, requiring dose adjustment).
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose) with minor biliary/fecal elimination (10-15%).
Renal: 60-70% as unchanged drug; biliary/fecal: 15-20% as metabolites; minor respiratory elimination.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant